Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: Prevention, therapy, and role of HaRas mutations

Molecular Cancer Therapeutics

Volumn 5, Issue 4, 2006, Pages 1073-1078

  Lubet, Ronald A ^a   Christov, Konstantin ^b   You, Ming ^c   Yao, Ruisheng ^c   Steele, Vernon E ^a   End, David W ^d   Juliana, M Margaret ^e   Grubbs, Clinton J ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Johnson and Johnson Pharmaceutical   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLNITROSOUREA; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB;

ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; RAT; TUMOR MODEL; WILD TYPE;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIMUTAGENIC AGENTS; APOPTOSIS; CARCINOGENS; CELL DIVISION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; GENES, RAS; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33646561823     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0398     Document Type: Article

References (23)

1. Cox AD, Der CJ. Ras family signaling therapeutic targeting. Cancer Biol Ther 2002;1:599-606.
2. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682-9.
3. Bassin RH, Simons PJ, Chesterman FC, Harvey JJ. Murine sarcoma virus (Harvey): characteristics of focus formation in mouse embryo cell cultures and virus production by hamster tumor cells. Int J Cancer 1968;3: 265-72.
4. Somers KD, Kirsten WH. Focus formation by murine sarcoma virus: enhancement by DEAE-dextran. J Virol 1968;36:155-7.
5. End DW, Smets G, Todd A, et al. Characterization of the anti tumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001;61:131-7.
6. Huggins C. Two principles in endocrine therapy of cancers: hormone deprival and hormone interference. Cancer Res 1965;25:1163-7.
7. Grubbs CJ, Moon RC, Sporn MB, Newton DL. Inhibition of mammary cancer by retinyl methyl ether. Cancer Res 1977;37:99-103.
8. Lubet RA, Gordon GB, Prough RA, et al. Modulation of methylnitrosourea- induced breast cancer in Sprague-Dawley rats by dehydroepiandrosterone: dose dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha Ras mutations. Cancer Res 1998;58:921-6.
9. Sukhumar S, Notario V, Martin-Zanca D, Barbacid M. Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature 1983;306: 658-61.
10. Eckert LB, Repasky GA, Ulku AS, et al. Involvement of Ras activation in human breast cancer signaling, invasion, and anoikis. Cancer Res 2004; 64:4585-92.
11. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
12. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999;53:167-76.
13. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995;1:792-7.
14. Omer CA, Chen Z, Diehl RE, et al. Mouse mammary tumor virus-Ki-RasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Res 2005;60: 2680-8.
15. Christov K, Shilkaitis A, Green A, et al. Cellular responses of mammary carcinomas to aromatase inhibitors: effect of vorozole. Breast Cancer Res Treat 2000;60:117-28.
16. Christov K, Ikui A, Shilkaitis A, et al. Cell proliferation, apoptosis and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen treated mammary tumors. Breast Cancer Res Treat 2003;77:253-64.
17. Armitage P. The chi-square test for heterogeneity of proportion after adjustment for stratification. J R Stat Soc B 1966;28:150-63.
18. Fiordalisi JJ, Johnson RL II, Weinbaum CA, et al. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-RAS4B resistance to farnesyltransferase inhibitors. J Biol Chem 2003; 278:41718-27.
19. Russo J, Russo IH. Atlas and histologic classification of tumors of the rat mammary gland. J Mammary Gland Biol Neoplasia 2000;5:187-200.
20. Lubet RA, Steele VE, De Coster R, et al. Chemopreventive effects of the aromatase inhibitor vorozole (R83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis 1998;19:1345-51.
21. Mijimolle N, Velasco J, Dubus P, Guerra C, et al. Protein farnesyltransferase in embryogenesis, adult homeostasis and tumor development. Cancer Cell 2005;7:313-21.
22. O'Regan RM, Khuri FR. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer? Endocr Relat Cancer 2004;11: 191-205.
23. Head J, Johnston SR. New targets for therapy in breast cancer: FTI inhibitors. Breast Cancer Res 2004;6:262-8.